stock-mb-logo-androidstock-mb-logo-ios
Stock Screener App
Free - Play StoreApp Store
InstallInstall
logo
Monopar Therapeutics IncMNPR
$70.931.45%-1.04

Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics Inc stock is traded at $70.93, with a volume of 55,218. It is down -1.45% in the last 24 hours and up +2.40% over the past month. Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
Previous Close:
$71.97
Open:
$71.45
24h Volume:
55,218
Relative Volume:
0.33
Market Cap:
$480.68M
Revenue:
-
Net Income/Loss:
-$14.99M
P/E Ratio:
-
EPS:
-$2.07
Net Cash Flow:
-$10.01M
1W Performance:
-1.18%
1M Performance:
+2.40%
6M Performance:
+19.67%
1Y Performance:
-7.20%
1-Day Range:
$70.31$73.19
1-Week Range:
$67.12$75.09
52-Week Range:
$50.07$124.82

Monopar Therapeutics Inc Stock (MNPR) Company Profile

Name
Monopar Therapeutics Inc
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE, USA
Employee
22
X
-
Next Earnings Date
-
Latest SEC Filings
SEC
MNPR's Discussions on X
X

 

Market Cap

 

Revenue

 

Net Income

 

Cash Flow

 

EPS

 

Monopar Therapeutics Inc Stock (MNPR) Financials Data

Similar to MNPR